Ribavirin Patent Expiration
Ribavirin is Used for treating infections and infestations by modulating cytokine responses in lymphocytes. It was first introduced by Bausch Health Us Llc
Ribavirin Patents
Given below is the list of patents protecting Ribavirin, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Rebetol |
US6790837 (Pediatric) | Ribavirin syrup formulations |
Oct 05, 2023
(Expired) | Schering |
| Rebetol | US6790837 | Ribavirin syrup formulations |
Apr 05, 2023
(Expired) | Schering |
| Rebetol |
US6172046 (Pediatric) | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
Mar 21, 2018
(Expired) | Merck Sharp Dohme |
| Rebetol |
US6172046 (Pediatric) | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
Mar 21, 2018
(Expired) | Schering |
| Rebetol |
US6472373 (Pediatric) | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
Mar 21, 2018
(Expired) | Merck Sharp Dohme |
| Rebetol |
US6472373 (Pediatric) | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
Mar 21, 2018
(Expired) | Schering |
| Virazole | US6150337 | Specific modulation of Th1/Th2 cytokine expression by Ribavirin in activated T-lymphocytes |
Nov 21, 2017
(Expired) | Bausch |
| Rebetol | US6172046 | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
Sep 21, 2017
(Expired) | Merck Sharp Dohme |
| Rebetol | US6172046 | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
Sep 21, 2017
(Expired) | Schering |
| Rebetol | US6472373 | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
Sep 21, 2017
(Expired) | Merck Sharp Dohme |
| Rebetol | US6472373 | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
Sep 21, 2017
(Expired) | Schering |
| Rebetol |
US6177074 (Pediatric) | Polyethylene glycol modified interferon therapy |
May 01, 2017
(Expired) | Merck Sharp Dohme |
| Rebetol |
US6177074 (Pediatric) | Polyethylene glycol modified interferon therapy |
May 01, 2017
(Expired) | Schering |
| Rebetol |
US6461605 (Pediatric) | Continuous low-dose cytokine infusion therapy |
May 01, 2017
(Expired) | Merck Sharp Dohme |
| Rebetol |
US6461605 (Pediatric) | Continuous low-dose cytokine infusion therapy |
May 01, 2017
(Expired) | Schering |
| Rebetol |
US6524570 (Pediatric) | Polyethylene glycol modified interferon therapy |
May 01, 2017
(Expired) | Merck Sharp Dohme |
| Rebetol |
US6524570 (Pediatric) | Polyethylene glycol modified interferon therapy |
May 01, 2017
(Expired) | Schering |
| Rebetol | US6177074 | Polyethylene glycol modified interferon therapy |
Nov 01, 2016
(Expired) | Merck Sharp Dohme |
| Rebetol | US6177074 | Polyethylene glycol modified interferon therapy |
Nov 01, 2016
(Expired) | Schering |
| Rebetol | US6461605 | Continuous low-dose cytokine infusion therapy |
Nov 01, 2016
(Expired) | Merck Sharp Dohme |
| Rebetol | US6461605 | Continuous low-dose cytokine infusion therapy |
Nov 01, 2016
(Expired) | Schering |
| Rebetol | US6524570 | Polyethylene glycol modified interferon therapy |
Nov 01, 2016
(Expired) | Merck Sharp Dohme |
| Rebetol | US6524570 | Polyethylene glycol modified interferon therapy |
Nov 01, 2016
(Expired) | Schering |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Ribavirin's patents.
Latest Legal Activities on Ribavirin's Patents
Given below is the list recent legal activities going on the following patents of Ribavirin.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Correspondence Address Change Critical
| 26 Aug, 2011 | US6790837 |
| Post Issue Communication - Certificate of Correction | 05 Mar, 2007 | US6790837 |
| Post Issue Communication - Certificate of Correction | 26 Oct, 2005 | US6461605 |
| Recordation of Patent Grant Mailed Critical
| 14 Sep, 2004 | US6790837 |
| Patent Issue Date Used in PTA Calculation Critical
| 14 Sep, 2004 | US6790837 |
| Issue Notification Mailed Critical
| 26 Aug, 2004 | US6790837 |
| Receipt into Pubs | 20 Aug, 2004 | US6790837 |
| Dispatch to FDC | 19 Aug, 2004 | US6790837 |
| Application Is Considered Ready for Issue Critical
| 19 Aug, 2004 | US6790837 |
| Receipt into Pubs | 18 Aug, 2004 | US6790837 |
Ribavirin's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Ribavirin:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
